Page 299 - Haematologica April 2020

PBSC with ATG vs. BM
P=0.01). In contrast, female donor to male recipient (HR=1.5, 95% C1: 1.3-1.7, P<0.001), and older age at transplantation (HR=1.07, 95% C1: 1.0-1.14, P=0.049) were associated with a higher incidence of cGvHD.
Relapse and non-relapse mortality
The 2-year CI of relapse was 25% (95% CI: 22-27%) in BMwithoutATGrecipientsversus28%(95%CI:25-31%) in PBSC with ATG patients (P=0.0496) (Figure 1C). After
Table 1. Patient characteristics among human leucocyte antigen-identical sibling donor (MSD) recipients
Variable
Follow up, median (95% CI)
Age of patient at HSCT (years), Median (IQR)
Sex, n (%) Male Female Missing
Karnofsky, n (%)
<80 ≥80 Missing
Status at transplant, n (%) CR1
CR2
Cytogenetic risk
Good1 Intermediate2 Poor3
Missing
AML type Primary
Secondary
Year of transplant, Median (IQR)
Sex mismatch, n (%) Female to male
CMV donor/patient, n (%)
-/-
+/-
-/+ +/+ Missing
Conditioning, n (%) Chemotherapy-based MAC4
TBI-based MAC
Post-grafting immunosuppression, n (%)
CNI + MTX CNI + MMF CNI alone Other/missing
ATG, n (%)
Thymoglobuline
Median (IQR) dose, mg/kg
ATG-Fresenius
Median (IQR) dose, mg/kg
Missing
BM without ATG (n=1633)
6.1 (5.9-6.5)
40 (30-48)
794 (49) 838 (51) 1
30 (2) 1270 (98) 333
1407 (86) 226 (14)
190 (16) 804 (70) 158 (14) 481
1537 (94) 96 (6)
2008 (2004-2012) 355 (22)
356 (24) 137 (9) 247 (17) 753 (50) 140
1118 (68) 515 (32)
1472 (90) 58 (4) 46 (3) 57 (3)
−
−
−
PBSC with ATG (n=1021)
2.3 (2.1-2.5)
48 (38-56)
535 (53) 480 (47) 6
29 (3) 950 (97) 42
893 (87) 128 (13)
62 (10) 428 (68) 136 (22) 395
908 (89) 113 (11)
2014 (2011-2016) 257 (25)
187 (19) 103 (10) 140 (14) 555 (56) 36
896 (88) 125 (12)
523 (51) 193 (19) 218 (21) 87 (9)
249 (30) 5.0 (5.0-5.6)
569 (70)
30 (30-35)
203
P
<0.0001 0.04
0.33
0.34
<0.0001
<0.0001
<0.0001 0.03
0.004
<0.0001
HLA: human leucocyte antigen; MSD: HLA-identical sibling donor; BM: bone marrow; PBSC: peripheral blood stem cells; CI: confidence interval; ATG: anti-thymocyte globulin; AML: acute myeloid leukemia; HSCT: hematopoietic stem cell transplantation; IQR: interquartile ranges; CR: complete remission; CMV: cytomegalovirus; MAC: myeloablative con- ditioning; TBI: total body irradiation; CNI: calcineurin inhibitor; MTX: methotrexate; MMF: mycophenolate mofetil;1defined as t(8;21), t(15;17), inv or del (16), or acute promyelo- cytic leukemia, these abnormalities only or combined with others; 2defined as all cytogenetics not belonging to the good or high risk (including trisomies); 3defined as 11q23 abnormalities, complex karyotype, abnormalities of chromosomes 5 and 7; 4defined as use of ≥ 6 Gy TBI, busulfan > 8 mg/kg, or melphalan > 140 mg/m2.
haematologica | 2020; 105(4)
1141